In a recent article over at genengnews.com Sue Pearson discusses ‘Antibody Mimetics – More effective treatments for solid tumors?’ and the use of Avacta Group plc (LON:AVCT) Affirmers.
Alastair Smith, Chief Executive told DirectorsTalk:
“The recent Avacta London Science Day was a great success bringing together world-leaders in cancer immunotherapies with an audience made up of shareholders, analysts, fund managers and press. Genetic Engineering and Biotechnology News have provided a review of the day and highlighted the power of small, potent antibody mimetics.”
You can read the full article here ‘Antibody Mimetics – More effective treatments for solid tumors?’
Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.